To view this email as a web page, click here.
October 18, 2019
 
SWAP-TWO shows anatomic improvement: 6-month interim analysis
image description here An initial 6-month interim analysis suggests switching agents can substantially improve anatomic outcomes while maintaining vision gains.

Find out
 
DNA analysis: Unraveling role of genetics in DR pathogenesis
image description here Though much is known about diabetic retinopathy (DR), the mechanisms underlying its etiology are still unclear. Learn what researchers are discovering about how genetic factors play a key role in the onset and progression of this disorder.

Find out
 
ADVERTISEMENT
Be curious. Be excited. Be informed.
Novartis is pleased to announce that BEOVU® (brolucizumab-dbll) injection has been approved by the Food and Drug Administration (FDA) and is now available. Learn more 
© 2019 Novartis 10/19 BVU-1381297
 
RELATED ARTICLES
 
Retina risk app tool empowers diabetic patients worldwide
Anti-VEGF expansion treats all DR stages
Determining DR progression: Much work still needs to be done
Laser treatment for DME: Still a place at the table?
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.